Angiogenesis induced by growth-factor releasing microspheres can be an off-the-shelf and immediate alternative to stem cell therapy for acute myocardial infarction (AMI), independent of stem cell yield and co-morbidity induced dysfunction. Reliable and prolonged local delivery of intact proteins such as VEGF is however notoriously difficult. Our objective was to create a platform for local angiogenesis in human-sized hearts, using polyethylene-glycol/polybutylene-terephthalate (PEG-PBT) microspherebased VEGF 165A delivery. PEG-PBT microspheres were biocompatible, distribution was size dependent and a regimen of 10·10 6 15µm microspheres at 0.5·10 6 per minute did not induce cardiac necrosis.
Introduction
Stem cell therapy for acute myocardial infarction (AMI), sought after to facilitate cardiac repair, has shown promise to improve cardiac function and patient outcome (12) . However, outcome parameters vary widely (11) and are not always reported well (40). Rather than trans-differentiation of stem cells into cardiomyocytes, the postulated mechanism of stem cell action is through paracrine factors, inducing anti-apoptotic effects, immunomodulation and regional angiogenesis (30). Improved angiogenesis or maintenance of the pre-existing microvascular bed is not only a prerequisite for cardiac regeneration, but also for cardiac healing through improved or maintained perfusion. It allows for access of leukocytes and facilitates scar stabilizing processes such as fibrosis and debridement.
Autologous stem cell therapy however, is delayed hours to days due to cell harvesting and cell culture steps, and quality and viability may vary with co-morbidities (14, 15) . In addition, it has been suggested that early post-AMI regional inflammation may impair stem cell function. This implies that stem cell therapy depends heavily on quality of the cells and, importantly, cannot be used immediately following a percutaneous coronary intervention (PCI) which is the preferred AMI treatment. This leaves acute and reperfusion induced injury such as no-reflow untreated.
Microsphere (MSP) therapy, releasing angiogenic or other therapeutic factors, could be an off-theshelf alternative to stem cells. It would make it independent from co-morbidity induced stem cell dysfunction and would be available for immediate delivery following PCI. It would also allow delivery of regional angiogenic agents or other pharmacotherapeutics before onset of irreversible reperfusion injury and before development of impaired (microvascular) perfusion i.e. no-reflow.
This timing is of particular importance as delivery of therapeutic agents before the occurrence of noreflow induced perfusion deficits, should allow optimal distribution of MSP and widens its therapeutic potential beyond angiogenesis to prolonged local delivery of other pharmaca.
We used an amphiphilic biomaterial composed of polyethylene glycol and polybutylene terephthalate (PEG-PBT) with adjustable release kinetics (PolyActive TM ). It is designed especially for stable protein delivery (2) (3) (4) (5) (6) and can theoretically harbor more than one growth factor per MSP for simultaneous release. Adjustable release kinetics of MSP allows control of diffusion and, subsequently, sequential release of multiple growth factors is possible when a mixture of growth factor specific MSP with dedicated release characteristics are given. Polyactive TM MSP delivery keeps proteins intact, protects them against proteolytic degradation and has shown excellent biocompatibility in implants (42).
PolyActive TM can be stored as an off-the-shelf therapy without loss of activity.
Many studies of growth factor induced angiogenesis have been performed in the past but these models invariably used chronic ischemia through permanent occlusion of a coronary artery. However, the clinical reality in Western Europe is that patients suffering an acute myocardial infarction are referred for PCI where possible, to relieve ischemia by immediate reperfusion. We therefore studied the efficacy of MSP induced angiogenesis using VEGF 165A as a model drug in a setting similar to that used for PCI by using a translational animal model of ischemia-reperfusion.
Materials and Methods

Source of VEGF 165A
Growth factor VEGF 165A, used for both cell culture studies and preparation of loaded MSP, was sourced from one supplier (Peprotech, New Jersey, United States). Growth factor for cell culture studies was diluted from fresh stock.
Preparation of VEGF 165A loaded Polyactive TM microspheres
Monodisperse formulations of placebo, high dose (~0.3 pg) and low dose (~0.1 pg) VEGF 165A -loaded PolyActive TM MSP (Octoplus, Leiden, The Netherlands) were prepared by a double emulsion (water-in-oil-in-water) method. VEGF 165A aqueous solution (0.5 % w/v) was emulsified by high shear mixing (Ultra-Turrax) into a solution of PolyActive TM , a copolymer of polyethylene glycol (PEG) and polybutylene terephthalate (PBT) with compositions, 1000PEGT80PBT20 or 1500PEGT77PBT23
(Polyvation, Groningen, The Netherlands) in dichloromethane (10 % w/w). This emulsion was pushed through a membrane (Nanomi, Oldenzaal, The Netherlands) with a uniform pore size specific for each desired MSP size, using nitrogen into a 0.5 % solution of polyvinyl alcohol (PVA, 13-23 kDa, Sigma, Zwijndrecht, The Netherlands), resulting in a suspension of uniformly sized micro droplets. Extraction and evaporation of the organic solvent resulted in formation of hardened MSP. After washing and final sieving through an absolute 20 µm sieve to remove aggregated samples, suspended MSP were frozen in water for injection and stored at -80 °C until use.
Microsphere size distribution and surface characteristics
Size distribution and the number of MSP per ml was determined by Coulter counter analysis (Coulter Counter Multisizer 3, Beckman Coulter, Mijdrecht, The Netherlands).
MSP shape and surface characteristics were studied by scanning electron microscopy (Jeol JSM6610LV at 5KV). Hydrated MSP were dried through graded ethanol series followed by a chemical drying step using hexamethyldisilazane (Sigma). Fully dried MSP were mounted using double sided conductive carbon tape and sputter coated (gold) before examination.
In vitro release kinetics of VEGF 165A microspheres
Since small increments in systemic VEGF levels are difficult to determine (23), release kinetics of drug-laden MSP were only determined in vitro. Release kinetics were assessed by placing 10·10 6 MSP in a gently and continuously swirled extraction medium at 37 °C (PBS + 0.05% Tween20) that precludes aggregation of proteins and stabilizes them for later analysis (7) . Total VEGF 165A release was measured at <1min (mimicking acute release), 2.5h (mimicking early reperfusion), then every day for 14 days followed by 21, 28 and 35 days post incubation. These time points were selected to mimic timing of the efficacy study described below. For size finding (myocardial MSP retention), Swine were sedated, anesthetized and instrumented as described before (41). In 11 animals, 1-5·10 6 placebo MSP ranging from 12-17µm
were injected intracoronary for dispersion into the healthy myocardium with an infusion rate up to 1.5·10 6 /min. After 2 hours of reperfusion, animals were euthanized and excised hearts were conventionally processed for histological MSP quantification (Resorcin-Fuchsin and infarct size determination (TTC), see supplemental data for full details.
To determine whether myocardial micro-infarctions were produced by MSP infusion, we investigated the acute effects of placebo MSP infusion in 4 healthy swine. Under fluoroscopic guidance, distally to the first marginal branch of the left circumflex coronary artery (LCx, to mimic the delivery as planned for the therapy study), 15 µm placebo MSP were infused in anesthetized swine through a microcatheter. Numbers of infused MSP varied from 5·10 6 to 20·10 6 and were infused with a rate of 0.5 or 1·10 6 MSP per minute (Table 1) . Serial blood sampling and quantification of markers for necrosis and follow-up infarct size measurements were executed as described before (41).
For biocompatibility studies, the sub-acute and chronic inflammatory response to placebo MSP were assessed in 6 swine infused with 5·10 6 15 µm MSP (0.5·10
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Thirty-two swine (31.4±0.4kg) were sedated as above and anesthesia was maintained with fentanyl (i.v. 20 µg/kg/hr). The LCx was occluded for 2 hours followed by reperfusion. Upon occlusion, anesthesia was switched from fentanyl to isoflurane inhalation anesthesia (10, 28) . Immediately upon reperfusion by deflation of the angioplasty balloon, 10·10 6 15µm MSP containing placebo, low or high dose VEGF 165A were infused (in 40ml saline, 2ml per minute, 0.5·10 6 particles per minute). The route of administration and the area of distribution of the MSP are illustrated in Figure 1 and shows that MSP are given through the lumen of the angioplasty balloon upon deflation while remaining at the original location, leading to MSP treatment of the area at risk only (i.e. subjected to ischemia), and not outside the area at risk. Anesthetized animals were monitored for 2.5 hours following reperfusion to serially assess biomarker release. Next, catheters were removed, the wound was closed and animals were allowed to recover. See supplemental data for full details.
Global and regional cardiac function by MRI
Global and regional cardiac function including microvascular obstruction was assessed, processed and analyzed in a blinded matter at one and five weeks after myocardial infarction and therapy using magnetic resonance imaging (MRI) as described before (25, 38), see supplemental data for full details.
Histology
At sacrifice of the anesthetized animal, a sternotomy was performed, the pericardium was carefully opened and after an overdose of pentobarbital, the aorta was cross-clamped and the vena cava opened. Immediately upon euthanasia, proximally to the aorta clamp, an infusion setup was placed to flush the arrested heart with approximately one liter of ice-cold saline to remove blood and plasma from the heart. The flushed heart was excised and cut into 5 transversal slices on a cooled cutting board.
Slices were sectioned into remote, border zone and infarct tissue and subsequently fixed in 3.5-4% buffered formaldehyde, in preparation for paraffin embedding. Area at risk (see Figure 1) is defined as the area subjected to ischemia and is the only area containing MSP. Infarct area is defined as the area showing extensive fibrosis and lack of cardiomyocytes. Border zone is defined as the area bordering the infarct, and does not contain microspheres. For microvascular density of the remote area, tissue was taken from the LV wall opposite of the infarcted area (i.e. septum).
Microvascular density measurement.
As arteriolar density does not change as a result of myocardial infarction (21), we measured total microvascular density in the microsphere treated infarct area reflecting changes in capillary density. 
Extracellular Matrix and regional cardiomyocyte presence
Collagen area and cardiomyocyte presence within the infarct region were quantified using a
Resorcin-Fuchsin staining. MSP containing areas (designated as having been subjected to ischemia)
were divided into 6 non-overlapping sections. Every section was analyzed to determine the percentage collagen (red stained areas) and cardiomyocytes (yellow stained cardiomyocytes).
Biomarkers for necrosis and inflammation
Serial blood samples were analyzed for markers for necrosis (41). Also, to assess the acute antiinflammatory response of VEGF 165A -drug-laden-MSP-therapy, tumor necrosis factor α (TNFα) and interleukin 6 (IL6) levels were quantified in blood samples obtained at baseline, at 2.5h of reperfusion and at 5wk follow-up according to manufacturer's instructions (R&D Systems). See supplemental data for full details.
Cumulative regional VEGF concentration per gram infarct tissue
The cumulative VEGF concentration eluted by 10·10 6 low and high dose MSP was calculated by dividing the mean in-vitro VEGF release in 35 days (i.e. 0.9 µg and 2.8 µg), by the weight of each infarction as determined by hFABP release at 50 min.
Statistical analysis
Data are presented as mean ± SEM. Data were analyzed with Sigmaplot (Version 11.0, Drunen,
The Netherlands) and SPSS (IBM SPSS statistics 21). Statistical significance was accepted when p<0.05. Two-way (time x treatment) repeated measures ANOVA or paired samples T-Test was used followed by post-hoc Bonferroni correction when appropriate. Statistical significance was accepted when p<0.05.
Results
In vitro studies of size distribution, surface characteristics and release kinetics of VEGF 165A
microspheres.
Determination of MSP size showed a similar diameter in all formulations in the therapy study 
In-Vitro angiogenic effects of VEGF 165A
The HCMVEC tube-formation assay under hypoxic conditions (Figure 3 ), as a marker for angiogenesis, showed a clear dose response to VEGF 165A in terms of significantly increased tube length (p=0.007) and number of junctions (p=0.021). Post-hoc analysis showed that this was dictated by the difference between 100 and 0 ng/g with a trend for 30 ng/g towards improved network formation. The low dose VEGF group reflects this value and therapy was steered towards a cumulative VEGF dose approximating 100 ng/g.
Size finding, safety and biocompatibility
The size finding study data obtained by intracoronary infusion of MSP of different size in swine myocardium, confirmed that smaller MSP of 12 µm were not well retained (6±1% as compared to 17 µm spheres). The latter showed impaired distribution with congestion of the microvasculature although TTC staining was negative. Therefore, 15 µm diameter MSP were selected for subsequent studies of safety and biocompatibility. In the safety or dose tolerance study with 15 µm spheres, the average MSP 
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Mortality following myocardial infarction was observed in 8 swine (25%) who died prematurely. Mortality was not different between groups: Non-convertible ventricular fibrillation during the infarct-reperfusion protocol occurred in 4 swine: 2 during coronary artery occlusion and 2 during reperfusion. No animals died during infusion of MSP. Two animals died within 48h post infarction of sub-acute cardiac complications. One animal died at one week due to severe heart failure and one animal died because of technical failure. All remaining 24 swine (n=8 per group) completed the protocol and were included for final blinded analyses.
Baseline characteristics and cumulative VEGF exposure
Infarct mass at baseline by markers of necrosis. To ascertain that infarct mass at baseline was similar in all groups, circulating hFABP levels were taken at 50 min of reperfusion to calculate infarct mass (41). Infarct masses did not differ between groups (Placebo: 13±2g; Low dose: 14±2g and High dose: 16±1g; p=0.40).
Cumulative VEGF exposure. Cumulative local VEGF concentration per infarct mass (infarct mass at baseline by hFABP divided by VEGF dose) showed that per gram infarcted myocardium, the low dose group received 0.07±0.01µg VEGF 165A , the high dose group received 0.35±0.06µg VEGF 165A .
Placebo MSP treated animals received no VEGF 165A.
Global and Regional cardiac function at 1 and 5 weeks post-AMI
To understand the early effects of VEGF therapy on cardiac function, one week post-AMI, global and regional myocardial function were assessed with cardiac MRI. Results ( Table 2 ) clearly
show that global and regional myocardial function are similar compared to placebo therapy.
Global and regional myocardial function were assessed again at 5wk post-AMI. Importantly, no significant differences were found between VEGF groups and placebo suggesting that VEGF did not have an effect on global and regional myocardial function either early (1wk) or late (5wk) post-AMI.
Inflammatory biomarker release
To understand the effect of VEGF therapy on inflammation, TNFα and IL6 were quantified at baseline, 2.5h of reperfusion and 5wk follow-up. Data are illustrated in Figure 5 and show that while placebo spheres showed a significant increase in TNFα release during reperfusion (p<0.01), levels decreased significantly to normal at 5wk follow-up (p<0.01). TNFα levels in both VEGF containing MSP formulations remained at baseline levels. A similar pattern for placebo was observed for IL6 and while the high dose group showed an increase at early reperfusion, this did not reach levels of statistical significance (p=0.15).
Histological analysis
Microvascular density measurements. To study the effect of VEGF on microvascular density in the infarct zone, Chalkley counts of the infarct area were normalized to the non-infarcted remote areas.
In contrast to placebo treatment (13±7% decrease in Chalkley score vs. remote, Figure 6 ), high dose treatment resulted in a significantly higher Chalkley score (10±6%, p<0.04 vs. placebo). This corresponds to a difference of approximately 739±278 vessels per mm 2 (p<0.05). The low dose group remained similar to the remote area, indicating a dose response effect. In figure 6 typical examples of microvascular density in the infarcted area are shown. Capillary density in the border zones in the placebo, low dose VEGF and high dose VEGF group (2045±125, 2168±115, 2223±134 vessels per mm resp.) were similar to the remote area and showed no signs of VEGF effects. Chalkley scores in MSP containing viable rim of the infarcted tissue, reliably measureable in a few animals (n=4 to 5/group), similarly did not show differences with remote in paired analyses.
Collagen and regional cardiomyocyte presence. To study whether differences in microvascular density affected infarct healing, we quantified the presence of collagen and cardiomyocytes in the area at risk, defined as the area containing MSP ( Figure 7 ). VEGF 165A therapy at 5wk post-AMI did not result in differences in total collagen content (placebo: 24 ±5%; low dose: 25±3%; high dose: 33±3% surface area, p=0.25) or changes in cardiomyocyte presence compared to placebo (placebo: 41±7%; low dose 37±5; high dose 27±5, p=0.21).
Discussion
The current study was performed to test the safety, biocompatibility and efficacy of controlled VEGF 165A release from degradable MSP as an off-the-shelf therapy for regional angiogenic therapy following acute myocardial infarction (AMI) in a setting of percutaneous coronary interventions (PCI).
Intracoronary delivery was initiated directly upon reperfusion of the infarct tissue to allow delivery of drug-loaded MSP before onset of reperfusion injury and no-reflow. This approach allows optimal MSP distribution within the area at risk before development of perfusion defects as a result of no-reflow.
Major findings
We observed that 15 µm MSP were effectively retained and distributed within the myocardium without inducing an acute or chronic local inflammatory response or (micro) infarction. MSP presence did not negatively affect cardiac function as compared to historic data with similar infarct size (heart rate 84±19 vs 80±4, stroke volume 60±11 vs 54±2) (28). VEGF-loaded MSP delivery in infarcted myocardium significantly reduced the acute release of the pro-inflammatory cytokines TNFα and IL6 during reperfusion. At follow-up, histology revealed dose dependent changes in microvascular density within the MSP treated infarct area as compared to the intrinsic non-ischemic control area. Per gram infarcted myocardium, a dose of 0.07±0.01µg VEGF 165A maintained-while 0.35±0.06µg VEGF 165A
increased-microvascular density. However, these changes did not translate to changes in scar composition (collagen and cardiomyocyte presence), or global and regional myocardial function by cardiac MRI at 1 or 5 weeks after AMI.
Microsphere Composition and Size
We found that 15 µm diameter MSP were effectively retained by the porcine myocardium, while 12µm MSP were not, and 17µm MSP impaired optimal distribution. MSP retention may not only be dictated by size but also by material properties since Poly(lactide-co-glycolide) MSP of 7 µm diameter were described to be retained well (1). Thus, every (bio)material for local drug delivery needs to be tailored individually to the intended microvascular bed for optimal MSP sizing. Especially in case of angiogenic MSP it is prudent to regulate MSP retention to prevent angiogenesis in unwanted areas.
Timing of MSP Delivery
The timing of infusion, immediately upon reperfusion of the ischemic myocardium, allows distribution before the major onset of reperfusion injury and no-reflow (31). This opens up new therapeutic options for treatment of no-reflow as systemic drug delivery will be limited by the development of microvascular perfusion defects within half an hour after onset of reperfusion. The timing of MSP therapy upon reperfusion is of great clinical potential as MSP can be infused directly following PCI, thus limiting additional procedural risks to the patient.
Inhibition of Acute Inflammation
Reperfusion following myocardial infarction is typically associated with the release of proinflammatory cytokines such as TNFα and IL6 (19). The main source of TNFα is suggested to be the monocyte/macrophage while others indicate that mast cells are the initial source of TNFα that subsequently gives rise to influx of monocyte/macrophages with the latter as the main source for IL6 (1, 19 ). However, cardiomyocytes and endothelium can also release TNFα when stimulated (26).
Given the chronic nature of our study, we were unable to assess the acute effect of VEGF MSP infusion on cardiac macrophage accumulation and mast cell degranulation in tissue. Consequently, we were unable to identify the source of these cytokines. Whether reduction of TNFα and IL6 is detrimental or protective for the reperfused myocardium is difficult to say. TNFα reduction can attenuate infarct size but TNFα can also increase the expression of cytoprotective proteins (26). In our study it did not translate to differences in myocardial function.
VEGF therapy and global function
VEGF 165A therapy in our study resulted in a dose-dependent increase in microvascular density but this did not translate into global or regional improvements of cardiac function as measured by cardiac MRI. However, we induced relatively small infarcts, and 5 weeks follow-up may be considered short. Previous results from our laboratory indicate that indeed, these conditions may not result in measurable global functional improvements at short term, despite regional improvements (28).
Our study is the first to report MSP based VEGF release for AMI in a setting of reperfused MI in a large animal model. Interestingly, approximately 57% of small animal VEGF studies that include functional measurements report improvements in global cardiac function and 50% of large animal studies show global functional improvements (Table 3 ), but these are mostly studied in a setting of chronic ischemia. No clear therapeutic optima, including timing of administration and total cumulative dosage, can be distilled from this previous work. Thus, differences in experimental conditions, including animal model, infarct size and therapeutic protocol, may underlie differences in therapeutic outcome.
VEGF elicits a dose-dependent increase in cardiac microvascular density
It is remarkable that so few studies report the total cumulative dose of administered VEGF or the dose normalized to bodyweight or infarct mass. Consequently an effective VEGF dosage remains to be established and may be species dependent. For example, two rat studies that applied a bolus-like administration of VEGF both report positive effects on global function while administering a striking 458-fold difference in cumulative growth factor dosage (11µg vs. 24ng) (36, 45). These results suggest that at least a broad range of therapeutic efficacy of VEGF for chronic MI exists. Our study, using a model of reperfused MI, shows that while placebo treatment resulted in loss of microvascular density in the infarct zone, a cumulative dose of 0.9µg VEGF (0.07±0.009µg per gram myocardium) preserved microvascular density whereas 2.8µg (0.35±0.057µg per gram myocardium) resulted in an increased microvascular density as compared to remote tissue. This demonstrates that VEGF indeed elicits dosedependent angiogenesis in the infarcted tissue.
When we place this outcome in perspective, it is striking that the effect of VEGF therapy in all previous studies consistently resulted in a significantly higher microvascular density of the infarct zone as compared to the microvascular density of control infarcts. This effect appears independent of dosage, therapeutic protocol or timing of administration. It must be noted however, that we were the only group to compare microvascular density within the infarct region to the intrinsic control (remote area). It may well be that while VEGF increased microvascular density in infarcted tissue as compared to control infarctions, it could still be lower than in the remote zone, which could affect long term outcome.
Route of administration and AMI-model
From a translational point of view, it is evident that an intravenous or intracoronary route of administration is less invasive as opposed to injecting growth factors directly into the myocardium.
Considering the potential tumorigenic potency and blood pressure lowering effects of VEGF (35), any bolus, either intravenous, intracoronary or intramyocardially, is less appropriate as it inevitably recirculates. VEGF, distributed via the microcirculation, binds avidly to endothelium and fibrin, where bound to the latter it still supports endothelial proliferation (24, 34). Slow and sustained VEGF delivery via degradable biomaterials following intracoronary delivery therefore seems a viable therapy as the growth factor can be more easily bound to the tissue, and subsequent circulating levels should remain low. So far, none of the studies in Table 3 used the clinically relevant intracoronary route of biomaterial mediated VEGF administration and no conclusions can be drawn whether the outcome would have differed. We speculate however, that optimal growth factor delivery and retention will be carrier dependent and needs to be tailored as is true for cell therapy (9). Clearly a permanent occlusion, as used in the vast majority of the studies summarized in Table 3 , is not representative for the clinical situation where interventions to restore perfusion of the ischemic territory is the golden standard in many countries. As a consequence, results obtained from these non-reperfused infarct studies will less likely predict the true effects of VEGF therapy following PCI for AMI.
Clinical relevance
In our model of reperfused MI, intracoronary delivery of VEGF by degradable MSP clearly resulted in an increased microvascular density, but not in improved cardiac function. Whether the changes in microvascular density would translate to a better long-term outcome beyond our 5 week period, is unknown. Thus, the long term benefit of increased microvascular density remains to be determined. The current study does serve as a proof of principle that chronic delivery of active protein using biocompatible polymers in the broader context is feasible. It is a versatile methodology which is not limited to regional and global cardiac scar remodeling therapy or to one specific protein, but rather might serve as a general platform for local drug delivery via the microvascular bed.
Limitations
The current formulation of microspheres showed an early (burst) release of VEGF in the in vitro study, which may have protected or stabilized the vascular bed from the acute ischemic insult resulting in attenuated release of inflammatory cytokines, but also results in lower sustained VEGF levels. We cannot exclude that this may have affected efficacy of angiogenesis. In addition, multiple growth factors might also have improved efficacy of angiogenic therapy. It is also generally accepted that comorbidities such as hypertension, diabetes and atherosclerosis, often present in patients suffering acute myocardial infarction, can affect angiogenesis. Therefore, studies in large animal models in which these risk factors are present would be useful, prior to testing angiogenic strategies in clinical trials.
Conclusions
Regional, controlled VEGF delivery leads to a dose dependent increase in microvascular density. This increase did not translate to changes in global or regional cardiac function or scar composition. Controlled regional VEGF delivery however is safe and feasible and supports the development of novel adjunctive off-the-shelf therapeutic applications. MTA = microsphere treated area; hsTnI = high sensitive troponin I (baseline: below detectable levels); hFABP = heart specific fatty acid binding protein (baseline: 6.1±1.1 ng/ml). ranging from 12-17µm were injected intracoronary for dispersion into the healthy myocardium with an infusion rate up to 1.5·10 6 /min. After 2 hours of reperfusion, the sternum was opened by a midsternal split, the coronary artery was occluded at the site of injection by inflating an angioplasty balloon. Evans Blue (Sigma, 15 % w/v in saline) was infused to demarcate the microsphere treated area (MTA). Then the animals were euthanized by an overdose pentobarbital and tissues were retrieved in preparation for triphenyl tetrazolium chloride (TTC) staining to determine infarct size (5). Tissues were fixed in buffered 4% formaldehyde in preparation for histology by paraffin embedding. Sections were stained by HE as a routine stain and by Resorcin-Fuchsin to stain microspheres black and were histologically analyzed for microsphere presence, distribution and inflammation.
Disclosures
Tables
For in-vivo safety, to determine whether myocardial micro-infarctions were produced by microsphere infusion, we investigated the acute effects of placebo microsphere infusion in 4 healthy swine.
Heart specific fatty acid binding protein (hFABP) and high sensitive Troponin I (hsTnI) were used as markers of cardiac necrosis. Animals were instrumented as described above and after placement of an intracoronary balloon catheter distally to the first marginal branch of the LCx coronary artery (to mimic the delivery as planned for the therapy study, see 2.7), 15 µm placebo microspheres were infused. Numbers of infused microspheres varied from 5·10 6 to 20·10 6 and were infused with a rate of 0.5 or 1·10 6 microspheres per minute (Table 1) . Serial blood sampling and quantification of markers for necrosis quantification and follow-up infarct size measurements were executed as described before (5).
For biocompatibility studies, the sub-acute and chronic inflammatory response to placebo microspheres were assessed in 6 swine infused with 5·10 6 15 µm microspheres (0.5·10 6 /min). Anesthesia was induced with thiopental sodium (i.v. 17 mg/kg) and maintained with isoflurane inhalation (1-3%).
After 5 days (n=3) or 28 days (n=3) animals were sedated and anesthetized as above. After sternotomy, the animals were euthanized, tissues retrieved and prepared for histology as described in the size finding study and examined for microsphere induced local inflammation. were maintained with heating pads and a sterile intravenous drip (Saline, 100ml/h). Electrocardiogram and blood pressure were monitored continuously. Under sterile conditions, an intra-arterial sheath was placed into a carotid artery. Next, 10,000 units of heparin and 250mg acetylsalicylic acid were administered as anticoagulation followed by 5,000 units of heparin every additional hour. The LCx was catheterized with a guiding catheter. Maximal transient coronary vasodilatation was induced for optimal balloon sizing with the selective infusion of 1 mg isosorbidedinitrate and coronary diameters were measured using a non-ionic contrast agent (Iodixanol) and dedicated software (CAAS, Pie medical, Eindhoven, The Netherlands). The occlusion and infusion site was carefully selected by at least two investigators and was always selected distal to the first marginal branch. An appropriately sized, coronary angioplasty balloon with a standard guide wire was carefully positioned under fluoroscopic guidance at the selected site of infusion, and the LCx was occluded for 2 hours. Upon occlusion, anesthesia was switched from fentanyl to isoflurane inhalation anesthesia as described before (1, 3) . After 2 hours of occlusion, the balloon was deflated and reperfusion was allowed. Immediately upon reperfusion, 10·10 6 microspheres containing placebo, low or high dose VEGF 165A were resuspended in a volume of 40ml saline and infused at 2ml per minute resulting in an infusion density of 0.5·10 6 particles per minute. Anesthetized animals were monitored for 2.5 hours following onset of reperfusion to serially assess biomarker release (see 2.10). Next, all catheters were removed, the wound was closed and animals were allowed to recover.
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MRI scanning, processing and analyses
Animals were sedated and intubated as described above (see 2.7). Anesthesia was maintained with fentanyl (20 µg/kg/h) and, when necessary, supported with thiopental sodium (100 mg bolus). Mechanical ventilation and peri-imaging breath-holds were performed using a mobile ventilator (Carina, Draeger, Zoetermeer, The Netherlands). When necessary, and always in absence of pain reflexes, muscle relaxation was achieved using pancuronium bromide (2-4 mg bolus). Cardiac MRI examinations were performed on a 1.5-Tesla clinical scanner (Signa HD, GE Medical systems, Milwaukee, WI, United States) using a dedicated cardiac four-channel phased array cardiac receiver coil. Repeated breath-holds and gating to the electrocardiogram were applied to minimize the influence of cardiac and respiratory motion on data collection. Both wk1 and wk5 cardiac MRI (CMR) protocols consisted of cine-MRI (myocardial function) and delayed enhancement MRI (DE-MRI, infarct size and no-reflow). Cine-MRI was performed using a steady-state, free-precession technique (FIESTA, GE Medical System). Using standard techniques to identify the major cardiac axes, two-chamber and four chamber cine-CMR images were obtained. The twoand four chamber end-diastolic images provided the reference images to obtain a series of short axis views.
This resulted in 8-12 cine breath-hold short-axis images to cover the entire left ventricle.
Delayed enhancement imaging was performed with a gated breath-hold 2-dimensional T1-inversion recovery gradient-echo sequence minimally 10 minutes after infusion of Gadolinium-diethyl-triaminepenta-acetic-acid (0.2 mmol/kg i.v., Gadobutrol ® , 1.0 mmol/ml, Bayer, Mijdrecht, the Netherlands) (4).
After MRI-imaging, animals received antibiotic prophylaxis as described in 2.7 and were allowed to recover (1 week post AMI) or transported back to the operating theatre for follow-up sacrifice.
MRI image processing and analysis
All images were transferred to a Microsoft Windows™ based personal computer for blind analysis using the CAAS-MRV program (version 3. 
